Latest Kyowa Kirin News & Updates

See the latest news and media coverage for Kyowa Kirin. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Kyowa Kirin

Global specialty pharmaceutical company

kyowakirin.com
Headquarters
Chiyoda-ku, Japan
Company type
Public company
Number of employees
5,000–10,000

Last updated

Latest news about Kyowa Kirin

Company announcements

  • Kyowa Kirin

    Kyowa Kirin plans state-of-the-art research hub

    The hub integrates Fuji and Tokyo sites at Yokohama to enhance drug discovery, translational research, and CMC collaboration as part of Vision 2030. Fuji and Tokyo sites may close.

  • Kyowa Kirin

    Kyowa Kirin releases FY2026 Q1 financial results

    Revenue reaches 118.5 billion yen, up 13% year-over-year. Core profit grows 78%. Forecasts updated.

  • Kyowa Kirin

    Kyowa Kirin initiates Japanese Phase 2 trial of ziftomenib

    First patient dosed in registrational trial for R/R NPM1-m AML. Plans regulatory filing post-trial. Collaborates with Kura Oncology.

  • Kyowa Kirin

    Kyowa Kirin discloses controlling shareholder details

    Provides information on parent Kirin Holdings' 55.22% ownership, relationships, transactions including 198,175 million yen loans, and independence measures.

Unlock all announcements with a

Media coverage

  • kabutan

    Kyowa Kirin lands with 95% increase in net profit for the 1-3 month period (1Q)

    Kyowa Kirin <4151> [TSE P] announced earnings (International Financial Reporting Standards = IFRS) after the market close (15:30) on May 7. The consolidated net profit for the first quarter of the fiscal year ending December 2026 (January-March) expanded to 12 billion yen, a 95.1% increase from the same period in the previous year, but the progress rate against the full-year plan of 75 billion yen was 16.0%, which was almost the same level as the 5-year average of 20.8%...

  • Nikkei

    Kyowa Kirin, Integration and Relocation of Research Bases to Further Strengthen Drug Discovery Capabilities ...

    Regarding the Integration and Relocation Plan of Research Bases to Further Strengthen Drug Discovery Capabilities ~Promoting strengthened collaboration of Drug Discovery × TR × CMC under Vision 2030 and Beyond (Medium- to Long-Term Plan)~ Kyowa Kirin Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President and CEO: Abdul Mallik; hereinafter "Kyowa Kirin") ...

  • Nikkei

    Kyowa Kirin stock price continues to fall sharply Despite 95% increase in net profit for January-March period, materials exhausted

    (10:30, Prime, code 4151) Kyowa Kirin fell sharply, dropping to 2154.50 yen, down 239 yen (9.98%) from the previous day. The consolidated results for January-March 2026 (IFRS) announced on the 7th showed net profit up year-on-year... We will send newsletters and Nikkei Electronic Edition campaign information, etc., to the email address you registered (you can unsubscribe after registration). The email address will be used only for the purpose of these email deliveries...

  • The Star

    CRYSVITA® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program

    Public drug coverage now provides eligible adults access to CRYSVITA, the only approved treatment for X-linked hypophosphatemia (XLH), a lifelong progressive disease...

Unlock all articles with a

Never miss news about Kyowa Kirin

Track Kyowa Kirin and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Kyowa Kirin competitors & trending companies

Browse news for competitors to Kyowa Kirin and other trending companies.